1. Estrogen receptor β promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer
- Author
-
Yuan Chen, Ronghao Wang, Emily Zixin Xing, Maio He, Shuyuan Yeh, Zhenwei Han, Cuntai Zhang, Weiwei Yu, and Jie Ding
- Subjects
0301 basic medicine ,Cancer Research ,MALAT1 ,medicine.drug_class ,Estrogen receptor ,Biology ,NEDD9 ,medicine.disease ,respiratory tract diseases ,Metastasis ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Estrogen ,030220 oncology & carcinogenesis ,Genetics ,medicine ,Cancer research ,Vasculogenic mimicry ,Signal transduction ,Lung cancer ,Molecular Biology - Abstract
While estrogen receptor β (ERβ) may impact the progression of non-small cell lung cancer (NSCLC), its linkage to alteration of the vasculogenic mimicry (VM) formation to influence the NSCLC cell invasion remains unclear. Here, we analyzed immunohistochemistry data from NSCLC tissues and found that ERβ-positive NSCLC female patients had worse survival outcomes than those of ERβ-negative NSCLC female patients. In vitro studies using multiple NSCLC cell lines also revealed that ERβ could increase the VM formation and cell invasion. Molecular mechanism dissection suggested that ERβ could increase the lncRNA-MALAT1 (MALAT1) expression via directly binding to the estrogen response elements (EREs) located on the promoter of MALAT1, which could then lead to (i) suppressing the miR145-5p and (ii) increasing the NEDD9 protein expression as miR145-5p can directly target the 3ʹ-UTR of NEDD9-mRNA. A preclinical study using the in vivo mouse model further confirmed the in vitro cell lines data. Together, results from the above studies demonstrated that ERβ can promote NSCLC VM formation and cell invasion via altering the ERβ/MALAT1/miR145-5p/NEDD9 signaling. Targeting this newly identified signaling pathway with small molecules may help the development of novel therapies to better suppress the NSCLC metastasis.
- Published
- 2018